Opinion|Videos|January 4, 2024

Future Targeted Therapy Approaches in NSCLC

Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.

Episodes in this series

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 1 Overview of Non–Small Cell Lung Cancer

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 2 The Role of Biomarkers in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 3 NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 4 The Role of TROP2 as a Biomarker in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 5 NSCLC: Preclinical Studies on TROP2 Expression

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 6 Lung Cancer Treatment: Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 7 Clinical Trial Data on Sacituzumab Govitecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 8 EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 9 Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 10 Antibody-Drug Conjugate Safety Profiles in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 11 Recent Data on Datopotamab Deruxtecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 12 NSCLC: Dato-DXd Combination Therapy

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 13 NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 14 Progress and Unmet Needs in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 15 Future Targeted Therapy Approaches in NSCLC

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC

October 8th, 2026

c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC

FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.

Dr Bazhenova on Taletrectinib Label Update and Subgroup Data in ROS1+ NSCLC

October 7th, 2026

Dr Bazhenova on Taletrectinib Label Update and Subgroup Data in ROS1+ NSCLC

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

Firmonertinib Misses PFS End Point in EGFR Exon 20–Mutant NSCLC

October 6th, 2026

Firmonertinib Misses PFS End Point in EGFR Exon 20–Mutant NSCLC

Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.

NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC

October 2nd, 2026

NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC

Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.

Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC

September 30th, 2026

Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC

FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer

Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma

c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC

Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC

Iberdomide Triplet Improves PFS by 51% in Phase 3 Myeloma Trial